Therefore, the Committee decided that the benefits of Icandra are greater than its risks for the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Zato je Odbor zaključil, da so koristi zdravila Icandra pri zdravljenju bolnikov s sladkorno boleznijo tipa 2, pri katerih samo z največjim peroralnim odmerkom metformina, ki ga še prenašajo, ni mogoče doseči zadostnega glikemičnega nadzora, ali pri tistih, ki se že zdravijo z vildagliptinom in metforminom v obliki ločenih tablet, večje od z njim povezanih tveganj.